Principal Data Architect: Snowflake Data Platform
Alexion
Principal Data Architect: Snowflake Data Platform
Alexion
Global biopharmaceuticals focusing on rare diseases
Role Overview
Key Responsibilities
1. Snowflake Platform Architecture
2. Enterprise Data Architecture
3. Snowflake Security & Access Architecture
4. Data Integration & Transformation Architecture
5. Architecture Governance & Design Authority
6. Platform Resilience & Operational Architecture
7. AI-Ready Data Architecture
Required Qualifications
Snowflake Expertise
Data Engineering & Architecture
Strong knowledge and practical experience in:
Language Requirements
Japanese
English
Preferred Qualifications
What We Expect from a Principal Data Architect
Date Posted
05-11月-2026Closing Date
30-1月-2027Alexion is proud to be an Equal Employment Opportunity and Affirmative Action employer. We are committed to fostering a culture of belonging where every single person can belong because of their uniqueness. The Company will not make decisions about employment, training, compensation, promotion, and other terms and conditions of employment based on race, color, religion, creed or lack thereof, sex, sexual orientation, age, ancestry, national origin, ethnicity, citizenship status, marital status, pregnancy, (including childbirth, breastfeeding, or related medical conditions), parental status (including adoption or surrogacy), military status, protected veteran status, disability, medical condition, gender identity or expression, genetic information, mental illness or other characteristics protected by law. Alexion provides reasonable accommodations to meet the needs of candidates and employees. To begin an interactive dialogue with Alexion regarding an accommodation, please contact [email protected]. Alexion participates in E-Verify.
Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.
Explore more opportunities at Alexion